Business Description

Organization Positron Corporation (the “Company” or “Positron”) was incorporated under the laws of the State of Texas in 1983. Unless the context requires otherwise, in this report the terms “we,” “us”, “our”, “the Company”, and “Positron” refer to Positron Corporation. Corporate History Positron Corporation was incorporated as a Texas corporation in 1983 with its corporate headquarters in North Tonawanda, New York. Nature of Business. Positron is a medical technology company that co-develops, manufactures and sells PET and PET-CT imaging systems, delivering high-performance, cost-effective molecular imaging solutions that empower healthcare providers to improve the diagnosis and treatment of cardiovascular disease and other critical conditions. By combining proprietary PET and PET-CT systems with comprehensive clinical and technical support, flexible financing, and a focus on operational efficiency, Positron makes advanced diagnostic imaging more accessible and sustainable for hospitals, outpatient centers, and physician practices. With a specialization in cardiac PET imaging and a growing presence in oncology and neurology, Positron stands at the forefront of innovation in nuclear medicine. Its systems are designed to enhance patient outcomes, maximize system uptime, and reduce total cost of ownership-offering unmatched clinical value and economic advantage in today’s healthcare environment. In 2023, the Company entered an expanded business cooperation / OEM Supply and Distribution / SKD Manufacturer Agreement with Shenyang Intelligent Neuclear Medical Technology Co. a subsidiary of Neusoft Medical Systems’ which secured exclusive rights for the North American market to sell/distribute PET,PET-CT and next generation PET-CT scanners in the future. The Company Positron Corporation is a medical technology company focused on advancing positron emission tomography (“PET”) imaging through the development, manufacture, and commercialization of PET and PET-computed tomography (“PET-CT”) imaging systems. The Company maintains a primary focus on cardiac PET imaging, which is widely utilized in nuclear cardiology for the diagnosis and management of cardiovascular disease. The Company’s solutions are designed to support diagnostic accuracy, improve patient outcomes, and enable cost-effective care for healthcare providers. 1 The Company’s imaging portfolio includes its dedicated PET system and its next-generation PET-CT platform. The Company is preparing for the introduction of its Affinity™ PET-CT 4D 64-slice system, which is intended to enhance clinical performance, workflow efficiency, and system capabilities. The Affinity PET-CT system is designed to support multiple clinical applications, including cardiology, oncology, and neurology. Through its strategic relationship with Shenyang Intelligent Nuclear Medical Technology Co. Ltd., a subsidiary of Neusoft Medical Systems, the Company collaborates on product development, engineering, and manufacturing. The Company intends to manufacture, distribute, and service its PET and PET-CT systems in its target markets. The Company also plans to pursue regulatory clearance for its Affinity PET-CT system through amendment of its existing U.S. Food and Drug Administration (“FDA”) 510(k) clearance. The Company’s collaboration with Neusoft also supports the continued development and production of its PET imaging systems and related technologies. The Company believes that its combined approach to product development, manufacturing, and service enables it to address evolving clinical and operational requirements within nuclear imaging. The Company’s strategy emphasizes accessibility, operational efficiency, and cost-effective system deployment. The Company believes it is positioned to address growing demand for PET-based imaging solutions across nuclear cardiology and other clinical applications. Positron’s Headquarters is in North Tonawanda, NY. Recent Developments On November 5, 2025, the Company granted options to purchase an aggregate of 5,150,000 shares of its common stock to certain members of management under the Company’s 2021 Equity Incentive Plan. The options were granted with an exercise price of $1.48 per share, which represents the quoted closing price on the grant date. The options fully vested on November 5, 2025, and will expire on November 5, 2030.…